FDA OKs Philips Breast Cancer Risk Assessment Software; Phil Meyer Comments

The Food and Drug Administration has approved a Royal Philips-built software application designed to evaluate breast density in women who undergo digital mammograms.

Philips’ Spectral Breast Density Measurement Application is intended to work with Philip’s MicroDose SI technology that is used for breast cancer screening, Philips said Thursday.

According to the company, the software works to compare the amounts of adipose and grandular tissues in the breast, then automatically correlate the resulting score to the BI-RADS breast density classification system.

Phil Meyer, Philips’ general manager and vice president for diagnostic X-ray and women’s health in North America, said the platform is built to help clinicians identify treatment methods for women with breast cancer.

The company designed the imaging app to meet state laws requiring health care providers to provide women with breast density information in mammogram reports.